Sep 18, 2019 - Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Sep 16, 2019 - The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Sep 13, 2019 - The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
Sep 11, 2019 - We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Sep 05, 2019 - It’s rejected a pair of drugs in the last six months.
Sep 05, 2019 - Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).
Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Sep 03, 2019 - Global Blood (GBT) focuses on the development of its lead product candidate, voxelotor - an oral, once-daily treatment for SCD.
Jul 30, 2019 - Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.